Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP;Estrategia multimarcador para estratificar el pronóstico en insuficiencia cardiaca. Valor de los marcadores neurohumorales: neprilisina frente a NT-proBNP

Revista Espanola de Cardiologia

Volumn 68, Issue 12, 2015, Pages 1075-1084

  Bayes Genis, Antoni ^a,b   Barallat, Jaume ^a,b   Galán, Amparo ^a,b   De Antonio, Marta ^a,b   Domingo, Mar ^a   Zamora, Elisabet ^a,b   Gastelurrutia, Paloma ^c   Vila, Joan ^d,e   Peñafiel, Judith ^d,e   Gálvez Montón, Carolina ^c   Lupón, Josep ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

failure; Heart; Neprilysin; NT proBNP; Prognosis Survival

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; MEMBRANE METALLOENDOPEPTIDASE; TROPONIN T; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ARTICLE; BODY MASS; DEATH; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; AGED; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; EPIDEMIOLOGY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MALE; METABOLISM; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; STATISTICS AND NUMERICAL DATA;

AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; EPIDEMIOLOGIC METHODS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; NEPRILYSIN; PEPTIDE FRAGMENTS; PROGNOSIS; STROKE VOLUME; TROPONIN T; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84951573429     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2015.07.002     Document Type: Article

References (28)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-847.
2. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358:2148-59.
3. Lupón J, De Antonio M, Vila J, Peñafiel J, Galán A, Zamora E, et al. Development of a novel heart failure risk tool: The Barcelona bio-heart failure risk calculator (BCN bio-HF calculator). PLoS One. 2014;9:e85466.
4. Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC, et al. Soluble ST2, high-sensitivity troponin T and N-terminal pro-Btype natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail. 2011;13:718-25.
5. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291:83-8.
6. Vijayaraghavan J, Scicli AG, Carretero OA, Slaughter C, Moomaw C, Hersh LB. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem. 1990;265:14150-5.
7. Bayés-Genís A, Barallat J, Galán A, De Antonio M, Domingo M, Zamora E, et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2014;65:657-65.
8. Bayes-Genis A, De Antonio M, Galán A, Sanz H, Urrutia A, Cabanes R, et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail. 2012;14:32-8.
9. Bayes-Genis A, De Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, et al. Head-tohead comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST-2 versus galectin-3. J Am Coll Cardiol. 2014;63:158-66.
10. Pencina MJ, D'Agostino Sr RB, Steyerberg EW. Extensions of net reclassification improvement calculations-measure usefulness of new biomarkers. Stat Med. 2011;30:11-21.
11. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-239.
12. Oremus M, McKelvie R, Don-Wauchope A, Santaguida PL, Ali U, Balion C, et al. A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods. Heart Fail Rev. 2014;19:413-9.
13. Ahmad T, Fiuzat M, Felker GM, O'Connor C. Novel biomarkers in chronic heart failure. Nat Rev Cardiol. 2012;9:347-59.
14. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
15. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54-61.
16. Oefner C, D'Arcy A, Hennig M, Winkler FK, Dale GE. Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon. J Mol Biol. 2000;296:341-9.
17. Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, et al; Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;10:1173-84.
18. Zamora E, Lupón J, De Antonio M, Vila J, Peñafiel J, Galán A, et al. Long-term prognostic value for patients with chronic heart failure of estimated glomerular filtration rate calculated with the new CKD-EPI equations containing cystatin C. Clin Chem. 2014;60:481-9.
19. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47:91-7.
20. Van Kimmenade RR, Januzzi Jr JL, Bakker JA, Houben AJ, Rennenberg R, Kroon AA, et al. Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol. 2009;53:884-90.
21. Zamora E, Lupón J, Urrutia A, González B, Mas D, Pascual T, et al. ?El índice de masa corporal influye en la mortalidad de los pacientes con insuficiencia cardiaca? Rev Esp Cardiol. 2007;60:1127-34.
22. Puig T, Ferrero-Gregori A, Roig E, Vazquez R, Gonzalez-Juanatey JR, Pascual-Figal D, et al. Valor pronóstico del índice de masa corporal y el perímetro de cintura en los pacientes con insuficiencia cardiaca crónica (Registro Español REDINSCOR). Rev Esp Cardiol. 2014;67:101-6.
23. Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014;176:611-7.
24. Bayes-Genis A, Ordonez-Llanos J. Multiple biomarker strategies for risk stratification in heart failure. Clin Chim Acta. 2015;443:120-5.
25. Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AH, et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail. 2012;5:183-90.
26. Daniels LB, Bayes-Genis A. Using ST2 in cardiovascular patients: A review. Future Cardiol. 2014;10:525-39.
27. De Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. Am Heart J. 2012;163:821-8.
28. Delgado JF, Oliva J, Llano M, Pascual-Figal D, Grillo JJ, Comín-Colet J, et al. Costes sanitarios y no sanitarios de personas que padecen insuficiencia cardiaca crónica sintomática en España. Rev Esp Cardiol. 2014;67:643-50.